Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/jtAxrz6ETd

Long term F/U of 80 systemic sclerosis pts Rx w/ autologous HSCT. W/ Med. 9.2 yrs F/U progression-free survival = 81%, 72% @5 yrs, & 60% @10 yrs. 18 pts died; death due to HSCT in 6%, SSc progression in 11%, CA in 2 (3%), serious infx 2 (3%), 34 (43%) maintained remission without https://t.co/l6RUf2Zqyw

FDA has approved the IL-23 inhibitor tildrakizumab (Ilumya) use in adults with active psoriatic arthritis (PsA), expanding the interleukin indications beyond moderate-to-severe plaque psoriasis. (Based on INSPIRE-1/2; >800 adults, 52-week RCTs) https://t.co/tCKZQwf74A https://t.co/Qffr1ZAMd7

Japanese retrospective cohort systemic sclerosis study shows adjunctive tofacitinib improved ower esophageal sphincter pressures (LESP). 50 SSc pts w/ esophageal Sxs Rx w/ Tofa or PBO x 24 wks. Tofa assoc w/ signif LESP increases & lower mRSS & IL-6 levels https://t.co/NNREBddiOi https://t.co/p6VujI8HWA

Dr. Lisa Stamp highlights crucial pharmacologic implications of COL use for gout flares in pts w/ comorbidities: - Dose adjustment in CKD - Be mindful of potential drug interactions @RheumNow #APLAR2026 https://t.co/efA7ptFF7Y

AxSpA SIG : Baraliakos - inflammation drives fatty lesions producing damage and osteoblastic activity @RheumNow @APLAR2026 https://t.co/GDFSwt2IOm

Why phenotype OA? Mechanisms, course and treatment response vary. Three knees at the same Kellgren-Lawrence grade 2 can differ: post-meniscal varus pain, obesity with synovitis, or widespread tenderness etc. X-ray grade alone misses this. OA:SIG #APLAR26 @RheumNow https://t.co/RWtq3ORGwc

Mease : future therapy - Be-Bold H2H Bime vs Rizi, Sonelokimab, Izokibep, Deucra, Zaso, Ico, TL1Ainhib @RheumNow #APLAR2026 https://t.co/Rv5hwnQnDl

Prof. AHoi presented their study on ESR as potential source of risk info in SLE 48% discordance bet ESR & conv. serology Isolated ⬆️ESR levels showed ⬆️ assoc with dse activity and flare; risk increases further if combi ⬆️ESR+low c3/4+antidsDNA @RheumNow #APLAR2026 https://t.co/BvC0OZFjd5

Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested. https://t.co/kV4Y7tvpC8

Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/cpusNcpYWd

Grappa Symposium: Leung Obesity in PsA - done deal @RheumNow #APLAR2026 https://t.co/3YQT4kiPer

AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype @RheumNow #APLAR2026 https://t.co/UYFnA3AyUM

An important and relevant reminder from @rheumarhyme on AI use @RheumNow #APLAR2026 https://t.co/7Ratb6aQOD

AI can be helpful in manuscript creation As the author: > always verify the draft - allow time to check > take full responsibility of the content - review and revise the final manuscript @RheumNow #APLAR2026 https://t.co/cQsEtDc7z1